Shuttle Pharmaceuticals Inc.
SHPH | NASDAQ
$3.76
+$0.29 (+8.36%)
At close: Sep 22, 2026, 4:00 PM ET
$3.91
+$0.15 (+3.90%)
After-hours:
Sep 22, 2026, 7:59 PM ET
Company Profile
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Key Executives
| Name | Position |
|---|---|
| Christopher Robert Cooper | Interim Co-CEO & Director |
| Ryan Trasolini | Co-Chief Executive Officer |
| Yuying Liang | Chief Financial Officer |
| Michael Vander Hoek | Vice President for Operations and Regulatory |
| Milton Brown | Co-Founder |
| Mira Jung | Co-Founder & Chief Scientific Officer for Biology |
| Tyvin A. Rich | Chief Clinical Officer & Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 02, 2026 | DEFA14A | Filing |
| Sep 02, 2026 | 8-K | Current Report |
| Sep 01, 2026 | 8-K | Current Report |
| Aug 28, 2026 | 8-K | Current Report |
| Aug 17, 2026 | NT 10-Q | Filing |
| Aug 17, 2026 | 8-K/A | [Amend] Current Report |
| Aug 13, 2026 | DEFA14A | Filing |
| Aug 13, 2026 | DEF 14A | Filing |
| Aug 03, 2026 | PRE 14A | Filing |
| Jul 15, 2026 | 4 | Filing |
Shuttle Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Aug 30, 2022 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Christopher Robert Cooper |
Contact Details
401 Professional Drive Gaithersburg,
Maryland 20879 United States
Stock Details
| Ticker Symbol | SHPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001757499 |
| CUSIP Number | 825693500 |
| ISIN Number | US8256935003 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove SHPH